enGene Holdings is trading at $1.66, up 5.06%, alongside a biotech-sector rally; no direct company-specific catalyst was identified.
- No fresh company-specific announcement was found for October 20. enGene’s latest listed release was its October 13 webinar announcement for a webinar held October 15.
- XBI rose 2.10% during the regular session amid sector-wide M&A and clinical-trial optimism; this is supporting context, not confirmation of a direct catalyst.